Brief Communication
Elevated Donor Cardiac Troponin I A Marker of Acute Graft Failure in Infant Heart Recipients James W. Grant, MD; Charles E. Canter, MD; Thomas L. Spray; Yvonne Landt; Jeffrey E. Saffitz, MD, PhD; Jack H. Ladenson, PhD; Allan S. Jaffe, MD One of the major causes of mortality in infant transplant recipients is early graft failure,' which accounts for a substantial percentage of the early 25% mortality associated with infant cardiac transplantation." 2 Previous studies have associated only a limited number of donor characteristics with the development of early graft failure or death in transplant recipients. 3, 4 The present study was designed to determine if evidence of donor cardiac damage detected by elevated blood levels of cardiac troponin I (cTnI), a sensitive and highly specific marker of cardiac damage, before harvest is related to posttransplantation graft survival. Because elevations of cTnl persist in blood for many days after cardiac injury, diagnosis with this marker requires less precise timing of blood sample acquisition. [5] [6] [7] Methods Patient Selection
The study group was composed of 19 donors whose hearts were used in 18 recipients less than 1 year of age from April 1991 through March 1994. During that time, a total of 27 transplantations were performed in infants less than 1 year of age at St Louis Children's Hospital. The selection of the 19 study patients was determined solely by the availability of donor serum collected at the time of organ harvest. None of the eight donor hearts excluded due to the absence of donor serum before transplantation manifested evidence of graft failure.
Information about the donors was obtained by review of the records provided by the UNOS information sheets. Donor cardiac function was evaluated by transthoracic echocardiograms performed at the referring hospital and was classified as 1, an above-normal shortening fraction (SF) or ejection fraction (EF) (SF >0.44 or EF >0.80; 2, a normal shortening fraction or ejection fraction (SF <0.44 and >0.28 or EF <0.79 and >0.58); and 3, a below-normal shortening fraction or ejection fraction (SF <0.28 or EF <0.58). Recipient information was obtained from the hospital records of each patient. Echocardiographic determinations were performed 8 hours to 1 week after transplant as part of posttransplant clinical evaluation using either a Hewlett-Packard model 77510A or a Toshiba model SSH-140A imaging system and a 5.5-MHz transducer. Shortening fractions in recipients were determined and analyzed in the same manner as the donor echocardiograms. The diagnosis of primary graft failure was made clinically, based on the presence of cardiogenic shock or intractable congestive heart failure in the absence of cellular or humoral rejection on endomyocardial biopsy. All clinical decisions regarding donor acceptability or graft failure and function were made without knowledge of the cTnI determinations.
cTnI and CK-MB Determinations
Serum was stored at -70°C, thawed, and assayed in batches. The concentration of cTnI was determined using a two-site immunoassay in a preliminary research application that uses two cTnI-specific monoclonal antibodies that recognize independent epitopes.5,6 In most normal adults, cTnI is undetectable. The upper level of the reference range is 3.1 ng/mL, based on nonparametric analysis of hospitalized adults without overt cardiac disease. The lower limit of detection is 1.5 ng/mL.56 CK-MB was determined as previously described using a commercially available immunoassay (Stratus CK-MB, Baxter-Dade). 6 The upper boundary of the reference range is 6.7 ng/mL. The lower limit of detection is 2.2 ng/mL. Abnormal values of cTnI and CK-MB were designated without knowledge of patient identity, clinical status, or other laboratory determinations.
Statistical Analysis
Comparisons were performed using Fisher's exact test and rank correlation coefficients with RS1 statistical software. Statistical significance was assigned to P values <.05.
Results
Donor serum cTnI levels are presented in descending order of magnitude in Table 1 and the clinical characteristics of the donors in Table 2 . Values ranges from a high of 70.5 ng/mL to undetectable. There were 8 donors with cTnI values >3.1 ng/mL; 5 of these 8 donor hearts were diagnosed as having graft failure. The 4 infants who were the recipients of these 5 hearts died (1 patient received 2 of the hearts that failed; No. 1, Table 1 ). These deaths accounted for the only mortality in the first 12 months after cardiac transplantation. Four of the donor hearts with graft failure had levels of cTnI in the donor of .10 ng/mL. The association of an elevated cTnI value and graft failure was statistically significant (P<.005). Patient 7, the only patient with cardiac graft failure and a level of <10 mg/mL but >3 ng/mL, was weaned successfully from cardiopulmonary bypass but experienced an extended cardiopulmonary arrest upon transfer to the intensive care unit. Pathological examination of this heart after retransplantation revealed diffuse myocardial necrosis and dystrophic calcification. In the remaining hearts examined histologically, there was also evidence of extensive subendocardial myocytolysis and myocardial coagulative necrosis ( Figure) . No evidence of humoral or cellular rejection or coronary arteriopathy was present in any of the hearts. The donor heart from patient 1 was not examined histologically. However, this patient could not be successfully weaned from cardiopulmonary bypass because of hypotension and poor cardiac function. No recipient of a heart from a donor with a cTnI level <3.1 ng/mL exhibited graft failure, required retransplantation, or died.
Clinical variables that were weakly correlated with the donor cTnI level were the estimate of the cardiopulmonary arrest time (P<.04, Table 3 ) and the time between cardiopulmonary arrest and organ harvest (P<.05, Table 3 ). None of the other donor characteristics, including the CK-MB value of the donor before transplantation, echocardiographic function, age, or creatinine were significantly correlated with the cTnl values. Posttransplant echocardiographic heart function also did not correlate with the pretransplant donor cTnI level (r=.27); patients with and without elevated cTnl levels had abnormal echocardiographic function ( Table  2 ). The (SIDS) was common among the donors with elevated cTnI values and was associated with prolonged out-ofhospital arrest times. Discussion These data define a significant relation between the cTnI concentration in the donor sera before harvest and the subsequent presence of fatal primary graft failure in infant cardiac transplant recipients. Five of the 8 hearts from donors with elevated values of cTnI developed intractable graft failure leading to death or retransplantation. In contrast, all hearts from donors with a cTnI value of <3.1 ng/mL were associated with successful transplantation. The likely explanation for the association of an elevated value of cTnI in donors and the adverse effects in recipients is that the elevated levels of cTnI reflect ischemic damage in the donor heart before harvest. This hypothesis is supported by the pathological findings of myocardial necrosis in the absence of evidence of rejection in the hearts of the patients who died. In each instance, the pathological findings were associated with elevated values of cTnI in the donors. It is not surprising that elevated cTnI values tended to occur in patients with out-of-hospital cardiopulmonary arrest such as in patients with the diagnosis of SIDS; Patient numbers are the same as in Table 1 . The line under patient 8 separates patients with elevated cardiac troponin values (above the line) from those with normal values (below the line). these patients experienced longer cardiac arrest times before resuscitation. CK-MB values were not uniformly elevated in the donors whose hearts subsequently developed graft failure. This is probably due to the fact that elevations of CK-MB do not persist as long in serum as do elevations of cTnI.5,6 In addition, CK-MB was elevated in some patients with normal values of cTnI who did not develop graft failure. These elevations in CK-MB could have been due to release of CK-MB from skeletal muscle, which has been reported to occur when skeletal muscle damage is severe. 6, 8 The use of a simple and rapid blood test such as cTnl may permit less restrictive donor selection criteria by providing for the screening of potential donor hearts biochemically. Previous studies of pediatric heart transplantation examining donor characteristics such as weight, diagnosis, level of support, and echocardiographic assessment of left ventricular function have failed to predict the success or failure of donor hearts after transplantation.3,410,12 This finding is not surprising, given the lack of standardization of assessments of global ischemic dysfunction by echocardiography, the preselection of "normal" echocardiographic evaluations in donors, the diversity of loading conditions present in donors, and the known autonomic dysfunction associated with brain death. In addition, studies of pediatric heart transplantation have been limited by the numbers of patients present with primary graft failure. Biochemical markers have not been measured previously in donors and related to the subsequent course of recipients. 3, 4, 9, 1041 Our promising results in a small cohort of patients suggest that a larger study to confirm our findings and to define the level of donor cTnI that provides the best predictive value is warranted. Because the donor hearts in infants are quite small, the use of an adult reference range may not be optimal, although it was highly predictive in this preliminary study. If it were possible to identify damaged donor organs, avoiding their use might reduce the incidence of acute graft failure. It also may be that strategies to protect recipients from cardiac graft failure could be developed based on a risk assessment predicated on the extent of injury of the donor heart as defined by cTnI.
The utility of cTnI values as a marker of donor myocardial damage for older children and adults is unclear but worthy of aggressive investigation. Conclusions It appears that biochemical evaluation of donor heart damage by measurement of cTN1 is likely to predict the response of the heart after transplantation in recipients less than 1 year of age.
